An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer.

摘要: Eighty-five breast carcinomas from the same number of patients have been assessed immunohistochemically using antiserum 21N for presence c-erbB-2 protein. Twenty-two had evidence advanced disease (tumour fixation or distant metastases) at presentation. Follow-up was a median 24 months. protein detected in majority cells 14 (16.5%) carcinomas, and to lesser extent further six (7%) tumours. There no relationship between staining stage, node status size but more poorly differentiated (36%) than well (17%) moderately (14%) (P = 0.02). significant association mortality 0.009) recurrence 0.0002). The relative risk death compared (after adjusting status, stage grade) 2.97 (95% confidence interval 1.29, 6.84) after similar adjustment 3.85 1.86-7.97). In this particular group immunoreactivity is an independent indicator poor short-term prognosis.